Immunology
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Sanofi Scores Clinical Win In Sixth Disease For Dupixent
The French major and partner Regeneron expect to file Dupixent for the rare skin disease next year after a Phase III trial of the blockbuster hit its primary and secondary endpoints.
Q3 Review: Editor’s Picks Of Scrip's Top Stories
From the latest COVID-19 advances to the emergence of a game changer for heart failure, Scrip’s editor in chief Eleanor Malone reviews the big stories of the past three months. Safety issues around JAK inhibitors and AAV vector-based gene therapy were also to the fore, while biopharma financing continued apace.
UCB Frustrated By FDA Failure To Inspect Facility For Psoriasis Drug
The Belgian group is the latest to be hit by the FDA's difficulties in address the growing backlog of facility inspections, leaving bimekizumab in limbo in the US, despite having just been approved as Bimzelx in Europe.
IGM Thinks Outside Oncology Box With Anti-Infective, Autoimmune Play
The company created two new divisions focused on the new disease areas, bringing in former executives from Bristol Myers Squibb and Sanofi Pasteur.
Bristol's High Profile TYK2 Inhibitor Disappoints In Ulcerative Colitis
Deucravacitinib is an oral drug in development for a wide range of autoimmune conditions, including psoriasis and psoriatic arthritis.
Anjarium To Pioneer Next-Generation Non-Viral Gene Therapies
Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.
MoonLake Takes SPAC Route To Challenge Novartis's Cosentyx
MoonLake of Switzerland is heading to the NASDAQ armed with $230m to take its tri-specific IL17A/IL-17F nanobody sonelokimab, acquired from Merck KGaA, into the highly competitive spaces of psoriatic arthritis, ankylosing spondylitis and hidradenitis suppurativa.
Sanofi And Amgen Make The Case For OX40 Drugs In Atopic Dermatitis
As the European Academy of Dermatology and Venerology congress closed its doors, two OX40 atopic dermatitis drugs from Sanofi and Amgen/Kyowa Kirin caught the eye.
Novartis Scores Another CSU Success With Remibrutinib
The Swiss group believes that remibrutinib, as well as its investigational IgE antibody ligelizumab, will complement standard of care Xolair and help it build a strong franchise for chronic spontaneous urticaria.
Incyte, Syndax Team Up On Chronic GVHD, But Some Uncertainties Remain
The deal could nevertheless give Incyte a competitive edge, especially with combination potential between its JAK inhibitors and Syndax’s axatilimab.
Evelo’s Phase II Data Suggest Strong Position In Mild-To-Moderate Psoriasis
Analysts say biotech’s EDP1815 may offer similar efficacy to Amgen’s Otezla, with better safety. Evelo says data offer new proof for its small intestinal axis approach to inflammatory disease.
Ex-Novartis Exec Joins Checkpoint Agonist-Focused Biotech
The Oxford university spin-out MiroBio has a senior leadership team in place, and aims to have its first checkpoint agonists in the clinic in 2022. Scrip spoke to its CEO about its plans.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.